Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cancer Biology & Therapy|November 20, 2009
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cellsCatherine Huang, Xiang M Zhang, Raluca T Tavaluc, et al.
The Journal of Molecular Diagnostics : JMD|September 19, 2016
Multiplexed Reference Materials as Controls for Diagnostic Next-Generation Sequencing: A Pilot Investigating Applications for Hypertrophic CardiomyopathyEmily M Kudalkar, Naif A M Almontashiri, Catherine Huang, et al.
Bioanalysis|November 18, 2021
Challenges with development of a pharmacokinetics assay to measure a variably glycosylated fusion proteinGizette Sperinde, Luna Liu, Keyang Xu, et al.
Plastic and Reconstructive Surgery|January 27, 2007
Autologous fat transfer national consensus survey: trends in techniques for harvest, preparation, and application, and perception of short- and long-term resultsMatthew R Kaufman, James P Bradley, Brian Dickinson, et al.
The AAPS Journal|October 1, 2025
A Fit-for-purpose Strategy for Clinical Immunogenicity Assessment of Multivalent Bispecific AntibodiesZhaojun Yin, Bob Y Liu, Ben Ordonia, et al.
Breast Cancer Research : BCR|September 3, 2011
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinibCatherine Huang, Catherine C Park, Susan G Hilsenbeck, et al.
Mabs|July 6, 2021
An integrated approach for characterizing immunogenic responses toward a bispecific antibodySivan Cohen, Shan Chung, Christoph Spiess, et al.
Breast Cancer Research and Treatment|May 31, 2012
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesAlbert C Chen, Ilenia Migliaccio, Mothaffar Rimawi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsMothaffar F Rimawi, Lisa S Wiechmann, Yen-Chao Wang, et al.
The Journal of Investigative Dermatology|October 26, 2013
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathwayTao Wang, Yingbin Ge, Min Xiao, et al.
Pageof 3